{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:35:31Z","timestamp":1792096531127,"version":"4.4.0"},"reference-count":57,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:p>Treatment, prognosis, and quality of life for people with cystic fibrosis (CF) have improved steadily since the initial description of the disease, but most dramatically in the past decade. In 2021, the median predicted survival increased to 53 years, compared with 17 years in 1970. The recent improvement in outcomes is attributable to the advent of cystic fibrosis transmembrane regulator (CFTR) modulators, small molecules that enhance the function of defective CFTR protein. The first CFTR modulator, ivacaftor, received Food and Drug Administration approval in 2011 to treat a single CFTR variant, comprising only 4% of those affected by CF. With the demonstration of efficacy, drug approval has been expanded to other variants. Multiple CFTR modulators used in combination with ivacaftor augment efficacy and increase the number of CFTR variants amenable to therapy. Approval of elexecaftor\/tezecaftor\/ivacaftor in 2019 increased the number of individuals who could benefit from highly effective modulator therapy (HEMT) to \u223c90% of the CF population in the United States. HEMT has been dramatically effective, with overall improvements in lung function, quality of life, nutritional status, and, in women, increased fertility. HEMT may delay the onset of other CF-related comorbidities. Although off-target effects, including hepatotoxicity, drug-drug interactions, and putative mental health issues can complicate use, modulator therapy has been generally well tolerated. Ten percent of people with CF have variants that are not amenable to modulator treatment. HEMT, despite its great cost and limited global access, has brought legitimate hope and changed the lives of a significant majority of individuals and families affected by CF in North America.<\/jats:p>","DOI":"10.1542\/peds.2023-062985","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T08:05:46Z","timestamp":1693987546000},"source":"Crossref","is-referenced-by-count":21,"title":["Delivering a New Future for People With Cystic Fibrosis"],"prefix":"10.1542","volume":"152","author":[{"given":"Elizabeth B.","family":"Burgener","sequence":"first","affiliation":[{"name":"Center for Excellence in Pulmonary Biology, Divisions of Pulmonary, Asthma, and Sleep Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Cornfield","sequence":"additional","affiliation":[{"name":"Center for Excellence in Pulmonary Biology, Divisions of Pulmonary, Asthma, and Sleep Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"issue":"2","key":"2023111414490179700_B1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/GIM.0b013e3181fa24c4","article-title":"Cystic fibrosis testing 8 years on: lessons learned from carrier screening and sequencing analysis","volume":"13","author":"Strom","year":"2011","journal-title":"Genet Med"},{"issue":"8","key":"2023111414490179700_B2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2023111414490179700_B3","unstructured":"CFTR2\n          . CFTR2. Available at: https:\/\/cftr2.org\/. Accessed May 11, 2023"},{"issue":"4922","key":"2023111414490179700_B4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.2772657","article-title":"Identification of the cystic fibrosis gene: chromosome walking and jumping","volume":"245","author":"Rommens","year":"1989","journal-title":"Science"},{"issue":"2","key":"2023111414490179700_B5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0092-8674(93)80063-K","article-title":"Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis","volume":"75","author":"Zabner","year":"1993","journal-title":"Cell"},{"issue":"9","key":"2023111414490179700_B6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"6753","key":"2023111414490179700_B7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/43977","article-title":"Virus treatment questioned after gene therapy death","volume":"401","author":"Lehrman","year":"1999","journal-title":"Nature"},{"issue":"18","key":"2023111414490179700_B8","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2023111414490179700_B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. Food and Drug Administration\u2019s experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"46","key":"2023111414490179700_B10","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2023111414490179700_B11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2023111414490179700_B12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2023111414490179700_B13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2023111414490179700_B14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1513\/AnnalsATS.201609-689OC","article-title":"Lumacaftor\/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR","volume":"14","author":"Rowe","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"2023111414490179700_B15","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1080\/14740338.2017.1372419","article-title":"The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis","volume":"16","author":"Talamo Guevara","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2023111414490179700_B16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1164\/rccm.201704-0717OC","article-title":"Tezacaftor\/ivacaftor in subjects with cystic fibrosis and F508del\/F508del-CFTR or F508del\/G551D-CFTR","volume":"197","author":"Donaldson","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"2023111414490179700_B17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"2023111414490179700_B18","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2023111414490179700_B19","unstructured":"Food and Drug Administration\n          . Elexecaftor tezecaftor ivacaftor (Trikafta) package insert, Food & Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf. Accessed April 8, 2023"},{"key":"2023111414490179700_B20","unstructured":"Chicago Tribune\n          . New drug appears to slow effects of cystic fibrosis, offering hope to long-suffering patients. Available at: https:\/\/www.chicagotribune.com\/lifestyles\/health\/sc-hlth-new-cystic-fibrosis-drug-0101-20191220-r3jjqdw3ozaknbdrxdfpzxrauu-story.html. Accessed April 8, 2023"},{"key":"2023111414490179700_B21","unstructured":"Cystic Fibrosis Foundation\n          . Hitting the Reset Button on My Life Because of Trikafta. Available at: https:\/\/www.cff.org\/community-posts\/2020-10\/hitting-reset-button-my-life-because-trikafta. Accessed April 8, 2023"},{"key":"2023111414490179700_B22","unstructured":"Cystic Fibrosis Foundation\n          . 2019 patient registry annual data report. Available at: https:\/\/www.cff.org\/Research\/Researcher-Resources\/Patient-Registry\/2019-Patient-Registry-Annual-Data-Report.pdf. Accessed May 7, 2023"},{"key":"2023111414490179700_B23","unstructured":"Cystic Fibrosis Foundation\n          . 2020 patient registry annual data report. Available at: https:\/\/www.cff.org\/sites\/default\/files\/2021-10\/2019-Patient-Registry-Annual-Data-Report.pdf. Accessed May 7, 2023"},{"key":"2023111414490179700_B24","unstructured":"Cystic Fibrosis Foundation\n          . 2021 patient registry annual data report. Available at: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf. Accessed May 7, 2023"},{"key":"2023111414490179700_B25","unstructured":"NACFC\n          . NACFC 2022 | S22: where has all the sputum gone? Detecting and diagnosing infections without sputum. Available at: https:\/\/www.youtube.com\/watch?v=jUr4n77OGzs. Accessed April 8, 2023"},{"issue":"10","key":"2023111414490179700_B26","doi-asserted-by":"crossref","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"issue":"2","key":"2023111414490179700_B27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcf.2020.11.008","article-title":"Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation","volume":"20","author":"Guimbellot","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"2023111414490179700_B28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2023111414490179700_B29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2021.09.010","article-title":"CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis","volume":"21","author":"Gould","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2023111414490179700_B30","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis [published online ahead of print May 2, 2023]","author":"Schembri","journal-title":"J Cyst Fibros"},{"issue":"3","key":"2023111414490179700_B31","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ppul.25781","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on vitamin D absorption in cystic fibrosis patients","volume":"57","author":"Wright","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"2023111414490179700_B32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"2023111414490179700_B33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.rmed.2017.08.026","article-title":"Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience","volume":"131","author":"Dagan","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"2023111414490179700_B34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1513\/AnnalsATS.202101-057OC","article-title":"Impact of cystic fibrosis transmembrane conductance regulator therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient-reported outcomes","volume":"19","author":"Beswick","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"21","key":"2023111414490179700_B35","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2023111414490179700_B36","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.202102-0278OC","article-title":"Magnetic resonance imaging detects progression of lung disease and impact of newborn screening in preschool children with cystic fibrosis","volume":"204","author":"Stahl","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"2023111414490179700_B37","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.3390\/jcm10214884","article-title":"Lung clearance index in children with cystic fibrosis during pulmonary exacerbation","volume":"10","author":"Walicka-Serzysko","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"2023111414490179700_B38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/0002-9378(70)90254-1","article-title":"Cervical mucus in cystic fibrosis: a possible cause of infertility","volume":"108","author":"Oppenheimer","year":"1970","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2023111414490179700_B39","doi-asserted-by":"crossref","first-page":"e001289","DOI":"10.1136\/bmjresp-2022-001289","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"3","key":"2023111414490179700_B40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jcf.2021.01.007","article-title":"Challenges in the use of highly effective modulator treatment for cystic fibrosis","volume":"20","author":"Ramos","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2023111414490179700_B41","unstructured":"Food and Drug Administration\n          . Ivacaftor (Kalydeco) package insert, Food and Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203188s022l_207925s003lbl.pdf. Accessed April 8, 2023"},{"issue":"4","key":"2023111414490179700_B42","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"2023111414490179700_B43","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"2023111414490179700_B44","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"7","key":"2023111414490179700_B45","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7326\/L23-0112","article-title":"Treatment of fetal cystic fibrosis with cystic fibrosis transmembrane conductance regulator modulation therapy","volume":"176","author":"Blumenfeld","year":"2023","journal-title":"Ann Intern Med"},{"issue":"485","key":"2023111414490179700_B46","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"key":"2023111414490179700_B47","article-title":"Cystic Fibrosis Agents","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2012"},{"issue":"1","key":"2023111414490179700_B48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"2023111414490179700_B49","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide attempts in adolescents with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor therapy","volume":"22","author":"Arslan","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"2023111414490179700_B50","doi-asserted-by":"crossref","first-page":"00127","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res"},{"issue":"1","key":"2023111414490179700_B51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/thoraxjnl-2015-207488","article-title":"International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety","volume":"71","author":"Quittner","year":"2016","journal-title":"Thorax"},{"key":"2023111414490179700_B52","first-page":"35","article-title":"Left behind: the potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis","volume":"42","author":"McGarry","year":"2022","journal-title":"Paediatr Respir Rev"},{"issue":"10","key":"2023111414490179700_B53","first-page":"1721","article-title":"Minorities are underrepresented in clinical trials of pharmaceutical agents for cystic fibrosis","volume":"13","author":"McGarry","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"2023111414490179700_B54","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cpdd.914","article-title":"A randomized, double-blind, placebo-controlled, multiple dose escalation study to evaluate the safety and pharmacokinetics of ELX-02 in healthy subjects","volume":"10","author":"Leubitz","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2023111414490179700_B55","unstructured":"Vertex Pharmaceuticals Incorporated\n          . A phase 1 single dose escalation study evaluating the safety and tolerability of VX-522 in subjects 18 years of age and older with cystic fibrosis and a CFTR genotype not responsive to CFTR modulator therapy. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05668741. Accessed May 10, 2023"},{"issue":"1","key":"2023111414490179700_B56","first-page":"70","article-title":"Orphan drug pricing and costs: a case study of Kalydeco and Orkambi","volume":"15","author":"Hollis","year":"2019","journal-title":"Healthc Policy"},{"issue":"4","key":"2023111414490179700_B57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2023-062985\/1567648\/peds.2023-062985.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2023-062985\/1567648\/peds.2023-062985.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:53:34Z","timestamp":1699973614000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/152\/4\/e2023062985\/193891\/Delivering-a-New-Future-for-People-With-Cystic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,9,6]]},"published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2023-062985","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]},"article-number":"e2023062985"}}